HIV Part 3: Prevention & Treatment Flashcards

1
Q

What is PrEP?

A
  • Antiretroviral medications taken to PREVENT HIV
    infection in HIV-negative individual
  • Tool for preventing HIV along with other HIV
    prevention strategies (e.g., condoms, male
    circumcision, behavioral risk reduction)
  • Does not prevent other STIs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

More information about PrEP

A
  • TDF 300 mg (Tenofovir disoproxil
    fumarate) + FTC 200 mg (Emtricitabine)
  • Approved in Canada for HIV PrEP in 2016
    (TAF/FTC approved Dec 2020)
  • Dose: 1 tablet daily (TDF/FTC) with or
    without food [alternative dosing strategy
    “PrEP on demand”]
  • Not recommended if CrCL < 60 mL/min
  • PrEP not appropriate if unknown or
    positive HIV status
  • Highly effective (>90%) if adherent
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

HIV Preventive Care Continuum

A

HIV-Negative Person
Behavioral Risk
Reduction
(ALONE)
Pre-Exposure
Prophylaxis
(PrEP)
Nonoccupational
Postexposure
Prophylaxis
(nPEP)

HIV-Positive Person
Treatment as Prevention
(TasP)

Behavioral risk reduction, ongoing support, and outreach
occurs throughout the continuum

So we ideally, you know someone’s HIV negative. We want to regularly screen, and and you have provide information about how to reduce risk and then be able t0 0ffer
prep. If if they maybe are
someone who’s higher at risk of acquiring HIV.
there’s also again post exposure, prophylaxis as an option, and then using treatment of of HIV as also a preventiontool,

Viral load suppresed w tx to prevent community transmission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Pharmacists’ Role in PrEP

A

How can I
access PrEP?
Can I take with my
other medications?
What if I miss a
dose?
How long can I
take PrEP?
Are there any
side effects?
Why do I have to
go for frequent
lab tests?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

ELIGIBILITY CRITERIA FOR PREP –
GUIDELINES IN CANADA AND
ALBERTA

A

pretty much. All provinces now have publicly funded to prep for high risk groups

It’s important to have funding in place, because these drugs, even generics, I think, are both
$400 a month ish

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

PrEP eligibility guidelines
* MSM, Trans Women and Gender Diverse
People:

A

Condomless anal sex within last 6 months and any
of:
* Infectious syphilis or bacterial STI in past 12 months
* nPEP more than once
* Ongoing sexual relationship with HIV+ partner with
substantial risk of transmissable HIV (e.g. VL detectable
or HIV status unknown but from higher risk population –
MSM or PWID)
* HIRI-MSM risk score ≥ 11 (see resources)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HIRI-MSM
risk
assessment
tool

A

this was a a scoring system that was done in clinical trials.

if you’re younger. Or, again, if you had receptive anal sex in the last 6 months that would would get you on its own. A very high risk. Category

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

PrEP eligibility guidelines
* Heterosexual persons:
* People who inject drugs:

A
  • Heterosexual persons:
    – For HIV negative partner in an ongoing
    relationship with HIV positive partner involving
    condomless vaginal/anal sex where HIV positive
    partner has substantial risk of transmissible HIV
    (e.g. VL> 40 copies/mL) OR HIV status unknown
    but from higher risk population (e.g. MSM, PWID)
  • People who inject drugs:
    – sharing of injection drug use paraphernalia (e.g.,
    needles, syringes, etc
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How PrEP works

A
  • PrEP prevents HIV from
    establishing infection
  • Takes several days to
    establish protective
    levels of drug in
    mucosal tissue to
    prevent infection
    – Rectal tissue – 7 days
    – Vaginal tissue – 20 days

Crosses mucosal barriers starts to to infect local immune cells and start to replicate. And then it takes a few days, though, for then HIV to get into the blood and lymphatic system, and then start to spread and and seed throughout the body.

So prep. It starts working by preventing that infection to happen in the first.

even if someone had HIV and across the the mucus membranes. If you were taking medication that can interrupt that cycle that will prevent HIV from from continuing to infect immune cells and and getting more established early on.

it does take a bit of time to get absorbed and and to establish protective levels in in the tissues, that you might need it like rectal or vaginal tissues. So that’s just something to to be aware of that. People should be on it a minimum a week before high risk activities. But in terms of vaginal protection it can take even a bit longer than that.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Assessing Eligibility for PrEP

A

Individual is HIV negative (recent test) and is at high
risk of acquiring HIV infection
* No signs/symptoms of acute HIV in previous month
* No documented contraindications to FTC/TDF

  • Other laboratory tests:
  • Screening for HBV (vaccinate if susceptible), and HCV
  • STI screening
  • CBC, Scr, urinalysis at baseline

you need to confirm that the person is negative for HIV.
Requires hx taking to know if they are high risk
Lower risk - not funded by AB
No contra: renal fxn, severe osteoporosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Starting PrEP

A
  • Must be prescribed by designated prescriber (Alberta)
  • Initial prescription x 30 days (no automatic refills)
  • Discuss can take 7 days (or 20 days) to reach protective
    concentrations
  • Adverse events:
  • Common – headache, abdominal pain, flatulence
  • Other – decreased renal function, decreased BMD
  • Review if patient taking other drugs that may increase
    risk of TDF renal toxicity
  • Reinforce/discuss strategies for adherence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Follow-up Assessment (at least every ___
months)

A

q3mo
* Screen to see if still eligible for PrEP (follow-up HIV &
STI testing every 3 months)
* Refill prescription for no more than 90 days
* Requests for refill extension – discuss with designated
prescriber (case by case basis)
* Assess adverse effects
* Assess and reinforce adherence
* Individuals of childbearing age/potential: pregnancy tests
this drug can be used in pregnancy. But again, just just wanting to do a pregnancy test as well, because again. both with respect to HIV risk, but also for prevention of transmission to a child. If if there was a exposure. So pregnancy testing is is recommended.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Which of the following would you not tell Shawn
regarding HIV pre-exposure prophylaxis (PrEP)?
a. PrEP reduces the risk of HIV by more than
90% if taken regularly
b. Once you are stabilized on PrEP, you only
need to get bloodwork every 6-12 months
c. It can take several days after starting PrEP to
have protective concentrations (in rectal or
vaginal tissues).
d. Side effects of HIV PrEP include decreased
bone mineral density.

A

B

Blood work is is typically recommended every 3 months.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

You are working in an inner-city pharmacy and sustained a
needle-stick injury after giving a patient a flu shot. The source
patient has not been engaged in medical care and recent labs in
Netcare show a CD4 count of 124 cells/µL and HIV viral load of
48,000 copies/mL. What is the average risk of acquiring HIV
from a needlestick injury?
a. 0.3%
b. 3%
c. 10%
d. 25%

A

A

HCV is 3%
HBV 10%?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

PEP – Post-exposure prophylaxis
What is it?

A

– Combination antiretroviral therapy (cART) given to someone who may have been exposed to HIV
– 2- or 3-drug regimens used to prevent acquisition of HIV infection
* Depends on type of exposure and infection status of source

  • May be an occupational (e.g. needlestick injury) or nonoccupational exposure (e.g. sexual encounter, needlestick,
    etc)
  • cART should be given as soon as possible, within 72 hours
  • Refer to hospital emergency department for assessment if
    someone has had an exposure in past 72 hours

these medications should be start started as soon as possible, and within 72 h. So again, that just comes down to we know the sooner you take it the more likely it’s going to interrupt replication, and more than 3 days after exposure is is unlikely to to have much benefit.

Basically the the best thing to do is, refer people to the the local emergency department for assessment. All ers in the province have post exposure, prophylaxis, kits with with drugs in the emergency department, and they would get started assessed. And then, if if they need criteria and get started on those.

And then often get referred to an infectious disease specialist for follow up, and an ongoing prescription

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

PEP – Post-exposure Prophylaxis
* Preferred regimen

A

– Truvada® (tenofovir DF 300 mg/emtricitabine 200 mg) 1
tablet daily
* 3
rd drug: raltegravir 400 mg twice daily OR dolutegravir
50 mg daily
– Duration: 28 days
* In Alberta, occupational exposures covered by employer (e.g.
AHS) and non-occupational exposures covered by Alberta
Health

what about coverage? So if it’s an occupational exposure? It’s covered by the employment employer.
It would have to be part of either your insurance or or covered by your employer, and if there’s a non occupational exposure, so sexual assaults, or or even consensual situation, it’s covered by Alberta health, but it has to be approved by the medical Officer of health.

17
Q

read case 3 slide 26

A

ok

18
Q

Overview of Perinatal
Transmission

A

Overall risk of ~25% in the absence of intervention
– 80% occurs just before or during delivery
– Primary HIV probably the highest risk for in-utero transmission
* Breastfeeding – risk is ~ 0.5% per month in untreated motherinfant pairs
* Risk of transmission in women with VL < 50 copies/mL at
conception and throughout pregnancy is close to zero
– Opportunities to decrease risk of transmission even if mother is
untreated during pregnancy or started on ART late in pregnancy
* Available evidence suggest antiretrovirals do not cause
adverse birth outcomes

19
Q

Key Points for Prevention
* Pregnant Person
baby

A

Pregnant Person:
– Testing (opt-out; rapid HIV testing at delivery where
appropriate)
– BEFORE DELIVERY: Antiretrovirals (ARVs) during pregnancy
(ideally before pregnancy). Goal: suppressed viral load.
– DURING L & D: IV zidovudine + oral ARVs for the mother
* C-section if VL> 1000 copies/mL close to delivery
– AFTER DELIVERY: Continuation of ARVs

  • Baby:
    – oral zidovudine x 4-6 wks- start within 6 hours
    – formula feeding (or breastfeeding/chestfeeding - risk of
    transmission < 1% but not zero)
20
Q

Which antiretroviral drugs are preferred in
pregnancy? (in pregnant people not
previously on treatment)

A

▪ Preferred Dual NRTI backbone:
▪ Abacavir/lamivudine
▪ Tenofovir DF + emtricitabine or lamivudine
▪ Tenofovir alafenamide/emtricitabine
▪ 3
rd drug:
▪ INSTI – dolutegravir
▪ PI –darunavir/ritonavir

preferred third drug is is actually dolutegravir due to the amount of data we have in pregnancy from, particularly Botswana, who had moved to this agent a number of years ago. We have lots of data and pregnancy.